Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLM60 in Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT03553914Phase 2Withdrawn
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in peripheral T-cell lymphoma (PTCL) (3 arms), sponsored by Conjupro Biotherapeutics, Inc. Primary endpoints: Percentage of subjects experiencing AEs and SAEs at 8 months and Overall Response Rate at 19 months. Planned start Jan 2021; status: withdrawn.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03553914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553914.